Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core

被引:17
|
作者
Xu, Jin [1 ,2 ]
Ong, Esther H. Q. [3 ]
Hill, Jeffrey [3 ]
Chen, Anqi [1 ]
Chai, Christina L. L. [1 ,2 ]
机构
[1] ASTAR, ICES, Singapore 138665, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore
[3] ETC, Singapore 138669, Singapore
关键词
FLT3; Covalent inhibitor; Michael acceptor; Maleimide; Acrylamide; Resorcylic acid lactones; PROTEIN-KINASE INHIBITORS; RECEPTOR TYROSINE KINASE; IRREVERSIBLE INHIBITORS; THERAPEUTIC TARGET; DISCOVERY; POTENT; AFATINIB; ANALOGS; GROWTH; CANCER;
D O I
10.1016/j.bmc.2014.10.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of simplified ring-opened resorcylic acid lactone (RAL) derivatives were conveniently synthesized to target FLT3 and its mutants either irreversibly or reversibly. Our design of covalent FLT3 inhibitors is based on cis-enone RALs (e.g., L-783,277) that have a beta-resorcylic acid as the core structure. The designed compounds contain three types of Michael acceptors (acrylamide, vinylsulfonamide and maleimide) as potential covalent traps of a cysteine residue at the binding site of kinases. A variety of functional substitutions were also introduced to maximize the binding interactions. Biological evaluations revealed that compound 17, despite the presence of a highly reactive maleimide Michael acceptor, is a potent covalent FLT3 inhibitor which shows some specificity in cellular assays. On the other hand, compounds 2 and 6 containing acrylamide or vinylsulfonamide groups are reversible towards FLT3 binding, and are potent and selective inhibitors of mutant FLT3-ITD versus wt-FLT3. They also inhibit cell proliferation in FLT3-ITD expressing cell line MV-4-11 as compared to wt-FLT3 expressing cell line THP-1 and non-FLT3 cell lines (K562, HL60 and Hek-293T). (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6625 / 6637
页数:13
相关论文
共 50 条
  • [31] OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
    Bartholomew J. Eisfelder
    Caner Saygin
    Joseph Wynne
    Margaret W. Colton
    Mariafausta Fischietti
    Elspeth M. Beauchamp
    Jason X. Cheng
    Olatoyosi Odenike
    Gail Roboz
    Houda Alachkar
    Wendy Stock
    Blood Cancer Journal, 11
  • [32] OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
    Eisfelder, Bartholomew J.
    Saygin, Caner
    Wynne, Joseph
    Colton, Margaret W.
    Fischietti, Mariafausta
    Beauchamp, Elspeth M.
    Cheng, Jason X.
    Odenike, Olatoyosi
    Roboz, Gail
    Alachkar, Houda
    Stock, Wendy
    BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [33] Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
    Wang, Eunice S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 154 - 162
  • [34] Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy
    Hu, Shengquan
    Liu, Jing
    Chen, Sikang
    Gao, Jian
    Zhou, Yubo
    Liu, Tao
    Dong, Xiaowu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (12) : 1872 - 1877
  • [35] FLT3 Inhibitors in AML: Are We There Yet?
    Akshay Sudhindra
    Catherine Choy Smith
    Current Hematologic Malignancy Reports, 2014, 9 : 174 - 185
  • [36] Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)
    Ma, Fei
    Liu, Peng
    Lei, Min
    Liu, Jian
    Wang, Hongtao
    Zhao, Shaohua
    Hu, Lihong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 127 : 72 - 86
  • [37] FLT3 inhibitors in acute myeloid leukemia
    Wu, Mei
    Li, Chuntuan
    Zhu, Xiongpeng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [38] Novel FLT3 tyrosine kinase inhibitors
    Levis, M
    Small, D
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (12) : 1951 - 1962
  • [39] FLT3 Inhibitors in Acute Myeloid Leukemia
    Stone, Richard M.
    ONCOLOGIST, 2016, 21 : S2 - S2
  • [40] The current therapeutic landscape of FLT3 inhibitors
    Levis, Mark
    BLOOD ADVANCES, 2017, 1 (22) : 1944 - 1944